Prasugrel Hydrochloride

"Prasugrel Hydrochloride" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.

Descriptor ID	D000068799
MeSH Number(s)	D02.886.778.315 D03.383.606.420 D03.383.903.315
Concept/Terms	Prasugrel Hydrochloride Prasugrel Hydrochloride Hydrochloride, Prasugrel Prasugrel HCl HCl, Prasugrel CS 747 CS 747 747, CS CS-747 CS747 Prasugrel Prasugrel Efient Efient Effient Effient LY 640315 LY 640315 640315, LY LY640315 LY-640315

Below are MeSH descriptors whose meaning is more general than "Prasugrel Hydrochloride".

Chemicals and Drugs [D]
Organic Chemicals [D02]
Sulfur Compounds [D02.886]
Thiophenes [D02.886.778]
Prasugrel Hydrochloride [D02.886.778.315]
Heterocyclic Compounds [D03]
Heterocyclic Compounds, 1-Ring [D03.383]
Piperazines [D03.383.606]
Prasugrel Hydrochloride [D03.383.606.420]
Thiophenes [D03.383.903]
Prasugrel Hydrochloride [D03.383.903.315]

Below are MeSH descriptors whose meaning is more specific than "Prasugrel Hydrochloride".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Prasugrel Hydrochloride" by people in this website by year, and whether "Prasugrel Hydrochloride" was a major or minor topic of these publications.

Bar chart showing 17 publications over 9 distinct years, with a maximum of 3 publications in 2011 and 2013

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2007	0	2	2
2009	0	2	2
2010	0	2	2
2011	0	3	3
2012	0	1	1
2013	0	3	3
2014	1	0	1
2019	1	0	1
2021	0	2	2

Below are the most recent publications written about "Prasugrel Hydrochloride" by people in Profiles.

Gill K, Servati N, Flahive J, Fraielli K. Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. J Cardiovasc Pharmacol Ther. 2021 11; 26(6):625-629.

View in: PubMed
Soueid AE, Kassas I, Rade J, Kakouros N. Evaluation of a Real-World In-Hospital Antiplatelet-Switching Strategy Following Coronary Interventions: The SWITCH Study. J Invasive Cardiol. 2021 04; 33(4):E263-E268.

View in: PubMed
Hariri E, Lessard D, Gore J, Rade J, Goldberg R. Are We Optimizing the Use of Dual Antiplatelet Therapy in Patients Hospitalized with Acute Myocardial Infarction? Cardiovasc Revasc Med. 2020 02; 21(2):182-188.

View in: PubMed
Jakubowski JA, Zhou C, Winters KJ, Lachno DR, Howard J, Payne CD, Mant T, Jurcevic S, Frelinger AL. The effect of prasugrel on ADP-stimulated markers of platelet activation in patients with sickle cell disease. Platelets. 2015; 26(5):474-9.

View in: PubMed
Jakubowski JA, Zhou C, Jurcevic S, Winters KJ, Lachno DR, Frelinger AL, Gupta N, Howard J, Payne CD, Mant TG. A phase 1 study of prasugrel in patients with sickle cell disease: effects on biomarkers of platelet activation and coagulation. Thromb Res. 2014 Feb; 133(2):190-5.

View in: PubMed
Keaney JF. P2Y12 inhibition in patients with NSTEMI--can later be better? N Engl J Med. 2013 Sep 12; 369(11):1056-7.

View in: PubMed
Jakubowski JA, Zhou C, Small DS, Winters KJ, Lachno DR, Frelinger AL, Howard J, Mant TG, Jurcevic S, Payne CD. A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity. Br J Clin Pharmacol. 2013 Jun; 75(6):1433-44.

View in: PubMed
Wun T, Soulieres D, Frelinger AL, Krishnamurti L, Novelli EM, Kutlar A, Ataga KI, Knupp CL, McMahon LE, Strouse JJ, Zhou C, Heath LE, Nwachuku CE, Jakubowski JA, Riesmeyer JS, Winters KJ. A double-blind, randomized, multicenter phase 2 study of prasugrel versus placebo in adult patients with sickle cell disease. J Hematol Oncol. 2013 Feb 17; 6:17.

View in: PubMed
Saucedo JF, Angiolillo DJ, DeRaad R, Frelinger AL, Gurbel PA, Costigan TM, Jakubowski JA, Ojeh CK, Duvvuru S, Effron MB. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study. Thromb Haemost. 2013 Feb; 109(2):347-55.

View in: PubMed
Flaherty MP, Johnston PV, Rade JJ. Subacute stent thrombosis owing to complete clopidogrel resistance successfully managed with prasugrel. J Invasive Cardiol. 2011 Jul; 23(7):300-4.

View in: PubMed

People

Explore

Similar Concepts

Top Journals